Приказ основних података о документу
Effects of Apnea, Obesity, and Statin Therapy on Proprotein Convertase Subtilisin/Kexin 9 Levels in Patients with Obstructive Sleep Apnea
dc.creator | Milojević, Ana | |
dc.creator | Zdravković, Marija | |
dc.creator | Brajković, Milica | |
dc.creator | Memon, Lidija | |
dc.creator | Gardijan, Vera | |
dc.creator | Vekić, Jelena | |
dc.creator | Zeljković, Aleksandra | |
dc.creator | Stefanović, Aleksandra | |
dc.creator | Mihajlović, Marija | |
dc.creator | Ivanišević, Jasmina | |
dc.creator | Bogavac-Stanojević, Nataša | |
dc.creator | Radosavljević, Vojislav | |
dc.creator | Spasojević-Kalimanovska, Vesna | |
dc.creator | Ninić, Ana | |
dc.date.accessioned | 2022-07-26T09:16:23Z | |
dc.date.available | 2022-07-26T09:16:23Z | |
dc.date.issued | 2022 | |
dc.identifier.issn | 1011-7571 | |
dc.identifier.uri | https://farfar.pharmacy.bg.ac.rs/handle/123456789/4199 | |
dc.description.abstract | Objectives: Obstructive sleep apnea (OSA) is a common condition closely related to obesity, insulin resistance, dyslipidemia, and cardiovascular disease. The aim of this study was to explore the possible relationship between OSA and proprotein convertase subtilisin/kexin type 9 (PCSK9). Methods: Full-night polysomnography was performed on 150 participants who were divided into three groups: controls, OSA patients on statin therapy, and OSA patients not on statin therapy. Biochemical markers, plasma low-density lipoprotein (LDL) and high-density lipoprotein (HDL) subclasses, and PCSK9 were determined. Results: PCSK9 was highest in OSA patients on statins compared to the control group and to OSA patients not on statins (p = 0.036 and p = 0.039, respectively), after adjustment for body mass index (BMI). LDL diameter was greater in OSA patients not on statins compared to OSA patients on statins (p = 0.032). PCSK9 was highest in the group of patients with all three risk factors (diagnosed OSA, statins, BMI ≥25 kg/m2) compared to groups with no, one, and two risk factors (p = 0.031, p = 0.001, and p = 0.029, respectively). Presence of OSA, statin therapy, and BMI ≥25 kg/m2 when combined were independently associated with higher levels of PCSK9 when adjusted for antihypertensive therapy, small dense LDL, and HDL 3c subclass (odds ratio = 2.849; interquartile range [1.026–7.912], p = 0.044). Conclusion: Statin therapy was closely related to PCSK9. OSA along with obesity and statin use induces elevation of PCSK9. | |
dc.publisher | S. Karger AG Basel | |
dc.relation | info:eu-repo/grantAgreement/MESTD/inst-2020/200161/RS// | |
dc.rights | openAccess | |
dc.rights.uri | https://creativecommons.org/licenses/by-nc/4.0/ | |
dc.source | Medical Principles and Practice | |
dc.subject | Obesity | |
dc.subject | Obstructive sleep apnea | |
dc.subject | PCSK9 | |
dc.subject | Statins | |
dc.title | Effects of Apnea, Obesity, and Statin Therapy on Proprotein Convertase Subtilisin/Kexin 9 Levels in Patients with Obstructive Sleep Apnea | |
dc.type | article | |
dc.rights.license | BY-NC | |
dc.citation.volume | 31 | |
dc.citation.issue | 3 | |
dc.citation.spage | 293 | |
dc.citation.epage | 300 | |
dc.citation.rank | M22 | |
dc.identifier.doi | 10.1159/000524087 | |
dc.identifier.scopus | 2-s2.0-85134083646 | |
dc.identifier.fulltext | http://farfar.pharmacy.bg.ac.rs/bitstream/id/9959/Effects_of_Apnea_pub_2022.pdf | |
dc.type.version | publishedVersion |